Letter to the Editor: "Transdermal vs Oral Estrogen Therapy and Venous Thromboembolism: Upgrade the Level of Evidence" by

Pierre-Yves Scarabin (1) , Marianne Canonico (1) , Valérie Scarabin-Carré (1) , Emmanuel Oger (2, 3)

1 CESP - Centre de recherche en épidémiologie et santé des populations
2 Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes]
3 CIC - Centre d'Investigation Clinique [Rennes]

Scarabin PY, et meta-analysis by Mohammed et al (1) confirms the safety advantage of transdermal vs oral estrogens with respect to the risk of venous thromboembolism (VTE). Surprisingly, the quality of evidence is described as very low (see Table 4 in the report). We believe that this quality rating based on “the observational nature of the studies and inconsistency of results” is not appropriate...

Domains: Life Sciences [q-bio]

Pierre-Yves Scarabin, Marianne Canonico, Valérie Scarabin-Carré, Emmanuel Oger. Letter to the Editor: "Transdermal vs Oral Estrogen Therapy and Venous Thromboembolism: Upgrade the Level of Evidence" by. Journal of Clinical Endocrinology and Metabolism, 2016, 101 (2), pp.L30--31. ⟨10.1210/jc.2015-4248⟩. ⟨hal-01274220⟩